FREDERICK PIERCE II - 12 Nov 2025 Form 3 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Role
Chief Executive Office
Signature
/s/Mark Rosenblum, as Attorney-in-Fact
Issuer symbol
SLRX
Transactions as of
12 Nov 2025
Net transactions value
$0
Form type
3
Filing time
24 Nov 2025, 07:59:44 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
PIERCE FREDERICK II Chief Executive Office 2450 HOLCOMBE BLVD STE X, HOUSTON /s/Mark Rosenblum, as Attorney-in-Fact 24 Nov 2025 0001229055

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SLRX Common Stock 16,666 12 Nov 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SLRX Series A Preferred Stock 12 Nov 2025 Common Stock 50,619 Direct F1
holding SLRX Series A Warrants 12 Nov 2025 Common Stock 16,666 $1.50 Direct
holding SLRX Series B Warrants 12 Nov 2025 Common Stock 16,666 $1.50 Direct
holding SLRX Stock Option (right to buy) 12 Nov 2025 Common Stock 5,061 $4.94 Direct F2
holding SLRX Stock Option (right to buy) 12 Nov 2025 Common Stock 8,318 $50.26 By: Frederick E. Pierce II Living Trust date January 28, 2011 Pierce F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series A Preferred Shares are convertible into 141,734 shares of Common Stock. The Series A Preferred Shares have no expiration date, and convert automatically into shares of Common Stock following stockholder approval and satisfaction of certain Nasdaq listing standards.
F2 The Stock Options are exercisable following stockholder approval and satisfaction of certain Nasdaq listing standards.

Remarks:

Exhibit 24, Power of Attorney, is attached.